Description
A PDE5 inhibitor; increases lung cGMP levels, attenuates the development of compensatory right ventricular hypertrophy, and reduces pulmonary arterial wall thickening in a rat model of monocrotaline-induced pulmonary hypertension at 1 and 5 mg/kg; increases creatine clearance and decreases BUN and serum MDA levels in a rat model of renal ischemia-reperfusion injury; induces penile erections in conscious rabbits and in rabbits with acute spinal cord injury at 0.3 and 10 mg/kg
Formal name: 3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxy-benzenesulfonamide
Synonyms: DA-8159
Molecular weight: 516.7
CAS: 268203-93-6
Purity: ≥95%
Formulation: A crystalline solid